Mod GRF 1-29

Mechanism of action

GHRH receptor agonist. The four amino acid substitutions confer resistance to DPP-IV and other proteases while preserving the pulsatile GH-release profile that is considered more physiological than continuous stimulation. Typically stacked with ipamorelin or another GHRP.

Primary uses

• Growth hormone axis research
• Community "pulse" protocols stacked with GHRPs

Typical dosing

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Regulatory status

Not approved. Not distinct from CJC-1295 in the chemistry literature; the community treats "with DAC" and "without DAC" as two separate products, while vendors often label Mod GRF 1-29 as "CJC-1295 no DAC."

What we checked

Mod GRF 1-29 is a name used by sellers for a modified form of sermorelin; it has no paper of its own in the clinical literature. This section records what can be checked.

Identity, computed

This is GHRH(1-29) amide with four substitutions (D-Ala2, Gln8, Ala15, Leu27), the peptide part of CJC-1295 without its albumin-binding DAC group. The dataset's formula C152H252N44O42 agrees with the calculator.

Regulatory status, read October 5, 2026

Drugs@FDA: 0 records for “CJC-1295”. EMA medicines list: 0 records for “sermorelin”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. WADA 2026: section S2.2.4; WADA 2027: section S2.2.4.

What the maker or sellers claim

Claim, from research-chemical sellers: Mod GRF 1-29 gives natural growth hormone pulses with better stability than sermorelin. No published human study tests this product.

What the searches turned up

Danish customs seizures analysed in 2019 contained modified GRF 1-29 and analogues of GHRP-2, GHRP-6 and ipamorelin, each with an extra glycine added at the front, so anti-doping methods had to be updated (Gajda et al., 2019). Anti-doping laboratories detect GHRH analogues including sermorelin and CJC-1295 in urine. The human growth-hormone data usually cited for it come from CJC-1295 with DAC, a different, long-acting molecule (its sources are listed in the References).

What we looked for and did not find

No human trial of the version without DAC, no registry record and no regulator record. Growth hormone releasing factors are prohibited in sport under WADA S2.

References

1. [pubmed] Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." Am J Physiol Endocrinol Metab, 2006. PMID: 16822960.
2. [review] Walker RF. "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" Clin Interv Aging, 2006;1:307-308. PMID: 18046908.
3. [pubmed] Gajda PM, et al. "Glycine-modified growth hormone secretagogues identified in seized doping material." Drug Test Anal, 2019;11(2):350-354. PMID: 30136411.

Related peptides